Kazia Therapeutics' (KZIA) shares jumped 55% in recent Thursday trading after the company announced the regulatory approval and launch of a clinical trial evaluating the combination of its investigational drug paxalisib and immunotherapy in patients with advanced breast cancer.
The multi-center, open-label phase 1b study will assess the safety and efficacy of paxalisib combined with Merck's (MRK) Keytruda or Lynparza in women with triple-negative breast cancer, Sydney-based Kazia said Thursday in a statement.
The study will enroll 24 patients from cancer centers in Queensland with treatment lasting up to 12 months, the company said.
The trial also will evaluate a non-invasive liquid biopsy digital pathology platform, developed by scientists at the QIMR Berghofer Medical Research Institute, to monitor treatment progress in real time, through blood sample analysis, the company said.
Merck shares rose 0.5% in recent Thursday trading.
Price: 2.14, Change: +0.76, Percent Change: +54.79
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。